Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John West

Family Medicine Pineville, WV Physician Assistant

NPI 1295826576 CMS profile 59266

Main St, Family Healthcare Assoc INC, Pineville, WV 24874

Open in the dashboard

General payments

$5,523

365 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John West of Pineville, WV is reported in the CMS Open Payments database as having received $5,523 across 365 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $784 44
2024 General $812 55
2023 General $747 46
2022 General $1,288 78
2021 General $1,892 142

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John West
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to John West were reported at $784. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year John West Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $1,892 $137 $35–$551 $132
2022 $1,288 $137 $37–$512 $149
2023 $747 $149 $42–$545 $160
2024 $812 $156 $44–$560 $164
2025 $784 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $783 44 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $782 60 payments
  3. AstraZeneca Pharmaceuticals LP $556 31 payments
  4. GlaxoSmithKline, LLC. $530 36 payments
  5. Merck Sharp & Dohme Corporation $350 23 payments
  6. AbbVie, Inc. $347 26 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $227 15 payments
  8. Abbott Laboratories $222 12 payments
  9. Pfizer Inc. $210 19 payments
  10. RedHill Biopharma Inc. $196 15 payments
  11. Other $1,319 84 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,523 365 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $761 58 payments
  2. Ozempic $751 42 payments
  3. RYBELSUS $721 40 payments
  4. TRELEGY ELLIPTA $505 34 payments
  5. FARXIGA $497 28 payments
  6. VERQUVO $395 26 payments
  7. FreeStyle Libre 2 $222 12 payments
  8. UBRELVY $177 11 payments
  9. Movantik $173 12 payments
  10. COLOGUARD DNA CAPTURE REAGENTS $162 15 payments
  11. Other $2,907 201 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 197 drugs

Part D claims

13,669

Median for Family Practice: 1,826

Drug cost

$755,820

Median for Family Practice: $120,094

Branded share of claims

23.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 80 $75,261
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 100 $71,045
Eliquis Apixaban Brand 88 $53,892
Farxiga Dapagliflozin Propanediol Brand 70 $53,251
Januvia Sitagliptin Phosphate Brand 79 $50,736
Linzess Linaclotide Brand 63 $38,059
Tradjenta Linagliptin Brand 58 $37,852
Entresto Sacubitril/Valsartan Brand 54 $37,420
Jardiance Empagliflozin Brand 57 $35,970
Tresiba Flextouch U-200 Insulin Degludec Brand 29 $30,526

The 10 drugs with the highest cost, of 197 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
$175 — —
TRELEGY ELLIPTA
$134 100 —
RYBELSUS
$132 18 —
Ozempic
$114 80 —
VERQUVO
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

365 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record